share_log

Wedbush Maintains Outperform on Design Therapeutics, Lowers Price Target to $19

Benzinga ·  May 10, 2023 09:33

Wedbush analyst Laura Chico maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and lowers the price target from $20 to $19.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment